Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : Animal Health and VLPbio sign global collaboration agreement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/16/2019 | 03:38am EST
Wednesday - October 16, 2019
Bayer Animal Health and VLPbio sign global collaboration agreement
Bayer Animal Health to strengthen its technology portfolio for biological products

Monheim, Germany, October 16, 2019 - Bayer Animal Health GmbH and VLPbio - The Vaccines Company S.L. have signed a global collaboration agreement to discover and develop a new generation of immunotherapeutic solutions that address the high demand for innovative treatment options in the field of veterinary medicine.

Bayer Animal Health and VLPbio have agreed to jointly discover and develop immunotherapeutics for animals based on VLPbio´s technology, which is designed to induce specific immune responses against target animal diseases. The two companies will share knowledge about animal diseases and develop strategic approaches towards customer-focused treatment alternatives. The collaboration aims to create tools to shape the future of animal health and to develop new products for prevention and treatment of animal diseases, thereby improving animal well-being.

Dr. Douglas Hutchens, Bayer Animal Health's Head of Drug Discovery, External Innovation & Chief Veterinary Officer, said: 'This partnership will allow us to intensify our focus on immunotherapeutics. We are proud to collaborate with one of the most innovative start-ups in the industry and strongly believe that this collaboration will enhance our innovation capabilities.'

VLPbio CEO Pablo Gutiérrez commented: 'Our commitment to this collaboration is based on three competitive advantages of our company: the innovative potential of our technology, the experience and capacity of our team as well as a solid strategic plan. This position is also being recognized in the industry. VLPbio was one of 12 innovation showcase finalists to pitch for investment in their products and technologies in the field of Health at the Animal Health Investment Forum Europe 2019.'

About VLPbio
VLPbio is a technological company based out of Spain that develops novel vaccines and other immunotherapies against high-impact diseases in the veterinary field based on chimeric virus-like particles (Ch-VLPs). VLPbio uses a proprietary technology which acts as an antigens-display platform for a specific target and activates an immune response. The company has a strong and diversified portfolio of products under development targeting a global market of more than 1 billion euros. For more information, go to https://vlpbio.com/.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Disclaimer

Bayer AG published this content on 16 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 October 2019 07:37:11 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
11/13MEDIATION BETWEEN BAYER, PLAINTIFFS : U.S. mediator
RE
11/13Unilever Names Former Maersk CEO as Chairman
DJ
11/13BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
11/11BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
11/10BAYER : Global agreement supports FieldView expansion in Europe and other region..
PU
11/07BAYER : refinances 1.75 billion euro hybrid bond
PU
11/07BAYER : invests USD 50 Million in eGenesis Series B financing round
PU
11/07BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
11/05BAYER : Youth leaders take on the fight to feed a hungry planet
AQ
11/04BAYER : completes sale of Dr. Scholl's™ brand to Yellow Wood Partners
PU
More news
Financials (EUR)
Sales 2019 44 614 M
EBIT 2019 7 663 M
Net income 2019 2 982 M
Debt 2019 36 760 M
Yield 2019 4,03%
P/E ratio 2019 22,2x
P/E ratio 2020 13,4x
EV / Sales2019 2,30x
EV / Sales2020 2,10x
Capitalization 65 748 M
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 80,66  €
Last Close Price 70,50  €
Spread / Highest target 74,5%
Spread / Average Target 14,4%
Spread / Lowest Target -45,0%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG16.41%72 346
JOHNSON & JOHNSON1.78%345 486
ROCHE HOLDING AG22.39%257 315
MERCK AND COMPANY11.01%215 950
NOVARTIS19.44%203 065
PFIZER-16.15%202 549